Company intelligence / Profile preview

Exclaim!

West Chester, Pennsylvania, USA

Ownership: Private
Development stage: Other

Overview

Exclaim Therapeutics is a biotechnology company dedicated to advancing adoptive cell therapies for the treatment of solid tumors. The company utilizes its proprietary EXCLAIM™ (EXpanded Cancer Lymphocytes for Adoptive IMmunotherapy) platform to develop next-generation tumor-infiltrating lymphocyte (TIL) therapies. By optimizing the expansion and activation of patient-derived lymphocytes, Exclaim aims to overcome the limitations of current cell therapies in the immunosuppressive microenvironment of solid cancers. Their approach focuses on enhancing the potency and persistence of TILs to provide durable clinical responses for patients with high unmet medical needs.

Therapeutic areas: Oncology
Modalities: Cell therapyTumor-infiltrating lymphocytes
Industry: Biotech

Beyond the preview

Go deeper on Exclaim!.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exclaim!.

Explore the full profile